


Elizabeth H. S. Wyatt
Vice President
Corporate Licensing

Merck & Co., Inc.
One Merck Drive
P.O. Box 100, WS2A-30
Whitehouse Station NJ 08889-0100
Fax 908 735 1202
Tel 908 423 7918



January 16, 1998

Dr. Robert H. Harris
President
Federal Research Consultants
2139 Route 35
Holmdel, NJ 07733

*Copied to AL; Andre;
Dennis + Craig
Filed to R. Munzel 1/22/98*

Dear Dr. Harris:

Thank you for your letter of December 3, 1997.

The information provided on ADD 234037 (a novel antiepileptic with neuroprotective properties) has been recently reviewed by the Neuroscience Review and Licensing Committee. We regret that there is no current interest in pursuing further evaluation of the opportunity. The Merck Research Laboratories (MRL) indicate that there are a great many compounds with profiles similar to the profile of ADD 234037. The compound is not particularly sophisticated structurally.

We do, however, thank you for the opportunity of evaluating our interest.

Sincerely,

Elizabeth H.S. Wyatt

/ie
[CL980160.069]
uts1214